Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of just 7%. Its late diagnosis and limited treatment options contribute to poor outcomes. Immunotherapy has had little success due to PDAC’s dense and immunosuppressive tumor environment. Emerging mRNA v...

Full description

Saved in:
Bibliographic Details
Main Authors: Aariz Hussain, Areeba Fareed
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Journal of Genetic Engineering and Biotechnology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1687157X25000137
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850070258771034112
author Aariz Hussain
Areeba Fareed
author_facet Aariz Hussain
Areeba Fareed
author_sort Aariz Hussain
collection DOAJ
description Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of just 7%. Its late diagnosis and limited treatment options contribute to poor outcomes. Immunotherapy has had little success due to PDAC’s dense and immunosuppressive tumor environment. Emerging mRNA vaccines, such as autogene cevumeran (BNT122), show promise in enhancing treatment. Preliminary trials have reported prolonged survival with minimal side effects. Despite this progress, the complexity of PDAC remains a significant challenge. Continued research is essential to fully realize the potential of mRNA-based therapies in combating this deadly cancer.
format Article
id doaj-art-485045b7ff4c43479a77af48e8db7a7d
institution DOAJ
issn 1687-157X
language English
publishDate 2025-03-01
publisher Elsevier
record_format Article
series Journal of Genetic Engineering and Biotechnology
spelling doaj-art-485045b7ff4c43479a77af48e8db7a7d2025-08-20T02:47:36ZengElsevierJournal of Genetic Engineering and Biotechnology1687-157X2025-03-0123110046910.1016/j.jgeb.2025.100469Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccinesAariz Hussain0Areeba Fareed1Corresponding author.; Karachi Medical and Dental College, PakistanKarachi Medical and Dental College, PakistanPancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of just 7%. Its late diagnosis and limited treatment options contribute to poor outcomes. Immunotherapy has had little success due to PDAC’s dense and immunosuppressive tumor environment. Emerging mRNA vaccines, such as autogene cevumeran (BNT122), show promise in enhancing treatment. Preliminary trials have reported prolonged survival with minimal side effects. Despite this progress, the complexity of PDAC remains a significant challenge. Continued research is essential to fully realize the potential of mRNA-based therapies in combating this deadly cancer.http://www.sciencedirect.com/science/article/pii/S1687157X25000137Pancreatic cancermRNA vaccinesTreatmentChemotherapySurgeryPersonalized Medicine
spellingShingle Aariz Hussain
Areeba Fareed
Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines
Journal of Genetic Engineering and Biotechnology
Pancreatic cancer
mRNA vaccines
Treatment
Chemotherapy
Surgery
Personalized Medicine
title Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines
title_full Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines
title_fullStr Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines
title_full_unstemmed Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines
title_short Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines
title_sort personalized medicine in pancreatic cancer harnessing the potential of mrna vaccines
topic Pancreatic cancer
mRNA vaccines
Treatment
Chemotherapy
Surgery
Personalized Medicine
url http://www.sciencedirect.com/science/article/pii/S1687157X25000137
work_keys_str_mv AT aarizhussain personalizedmedicineinpancreaticcancerharnessingthepotentialofmrnavaccines
AT areebafareed personalizedmedicineinpancreaticcancerharnessingthepotentialofmrnavaccines